Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Axsome Therapeutics, Inc. (AXSM : NSDQ)

• Company Description    Axsome Therapeutics is a biopharmaceutical company focused on developing novel therapies for the management of central nervous system (CNS), disorders for which there are limited treatment options available. Number of Employees: 683

• Price / Volume Information    Yesterday's Closing Price: $138.15 Daily Weekly Monthly 20 Day Moving Average: 531,727 shares Shares Outstanding: 50.41 (millions) Market Capitalization: $6,964.51 (millions) Beta: 0.50 52 Week High: $141.36 52 Week Low: $75.56 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 13.51% 10.53% 12 Week 26.49% 21.25% Year To Date 63.28% 42.72%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL One World Trade Center 22nd Floor - NEW YORK,NY 10007 USA ph: 212-332-3241 fax: 212-320-0245 None http://www.axsome.com

• General Corporate Information    Officers Herriot Tabuteau - Chief Executive Officer and Chairman of the Board Nick Pizzie - Chief Financial Officer Roger Jeffs - Director Mark Coleman - Director Mark Saad - Director Peer Information Axsome Therapeutics, Inc. (CORR.) Axsome Therapeutics, Inc. (RSPI) Axsome Therapeutics, Inc. (CGXP) Axsome Therapeutics, Inc. (BGEN) Axsome Therapeutics, Inc. (GTBP) Axsome Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 05464T104 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 02/17/26 Share - Related Items Shares Outstanding: 50.41 Most Recent Split Date: (:1) Beta: 0.50 Market Capitalization: $6,964.51 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.71 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.75 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 41.97% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 02/17/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 94.46 Price/Cash Flow: - Price / Sales: 12.41 EPS Growth vs. Year Ago Period: 29.85% vs. Previous Quarter: -2.17% Sales Growth vs. Year Ago Period: 63.22% vs. Previous Quarter: 13.96% ROE 09/30/25 - -277.31 06/30/25 - -283.22 03/31/25 - -272.80 ROA 09/30/25 - -28.81 06/30/25 - -33.06 03/31/25 - -36.69 Current Ratio 09/30/25 - 1.57 06/30/25 - 1.57 03/31/25 - 2.03 Quick Ratio 09/30/25 - 1.50 06/30/25 - 1.51 03/31/25 - 1.96 Operating Margin 09/30/25 - -31.75 06/30/25 - -39.50 03/31/25 - -48.29 Net Margin 09/30/25 - -40.90 06/30/25 - -49.88 03/31/25 - -64.39 Pre-Tax Margin 09/30/25 - -41.05 06/30/25 - -50.05 03/31/25 - -64.37 Book Value 09/30/25 - 1.46 06/30/25 - 1.46 03/31/25 - 1.08 Inventory Turnover 09/30/25 - 2.46 06/30/25 - 2.61 03/31/25 - 2.39 Debt-to-Equity 09/30/25 - 1.66 06/30/25 - 1.66 03/31/25 - 3.48 Debt-to-Capital 09/30/25 - 62.39 06/30/25 - 62.41 03/31/25 - 77.67

Powered by Zacks Investment Research ©